Preview

PHARMACOECONOMICS. Modern pharmacoeconomics and pharmacoepidemiology

Advanced search

Search


Order results by:     
 
Issue Title
 
Vol 5, No 2 (2012) COST EFFECTIVENESS OF ORAL PERICALCITOL IN PATIENTS WITH STAGE III-IV CHRONIC KIDNEY DISEASE AND SECONDARY HYPERPARATHYREOSIS Abstract  similar documents
A. V. Rudakova
"... paricalcitoldecreases proteinuria in patients with chronic kidney disease (CKD) and hyperparathyreosis. ..."
 
Vol 5, No 3 (2012) PHARMACOECONOMIC EVALUATION OF TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS ON DIALYSIS WITH CINACALCET Abstract  similar documents
R. I. Yagudina, V. G. Serpik
"... D and phosphorbinders in patients with end-stage renal disease on dialysis. Comparison was carried ..."
 
Vol 9, No 2 (2016) PHARMACO-ECONOMIC ANALYSIS OF COST IN TERMS OF MAINTENANCE OF PREFERENTIAL MEDICINES PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE ON THE TERRITORY OF KRASNOYARSK REGION Abstract  similar documents
T. V. Gaygolnik, I. V. Demko, E. N. Bochanova, A. Yu. Kraposhina, N. V. Gordeeva, I. A. Soloveva
"... in particular of providing preferential medicines patients with сhronic obstructive pulmonary disease (COPD ..."
 
Vol 9, No 2 (2016) PHARMACOECONOMIC ANALYSIS OF THE THERAPY OF СHRONIC OBSTRUCTIVE PULMONARY DISEASE PATIENTS IN HOSPITAL CONDITIONS Abstract  similar documents
E. E. Vidyakina, S. V. Malchikova
"... Objective. To determine the priority used to vital drugs in сhronic obstructive pulmonary disease ..."
 
Vol 5, No 3 (2012) PHARMACOECONOMIC STUDY OVER USE OF ANTICHOLINERGIC BRONCHODILATORS (SPIRIVA AND ATROVENT) FOR TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE Abstract  similar documents
A. U. Kulikov, I. A. Komarov
"... Currently, chronic obstructive pulmonary disease (COPD) is a 5-largest cause of death worldwide ..."
 
Vol 6, No 2 (2013) COST-EFFECTIVENESS ANALYSIS OVER USE OF TYROSINE KINASE INHIBITORS (TASIGNA AND GLEEVEC) FOR TREATMENT OF CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE AS FIRST-LINE THERAPY FOR DE NOVO PATIENTS Abstract  similar documents
R. I. Yagudina, A. Yu. Kulikov, I. A. Komarov
"... oncology diseases), and mortality due to leukemia is 220 000 patients. Pharmacoeconomic evaluation ..."
 
Vol 10, No 3 (2017) The strategies of drug supply for patients with chronic hepatitis C Abstract  similar documents
E. V. Kornilova, A. D. Ermolaeva, M. G. Rusanova, D. A. Andreev, M. V. Davydovskaya, T. N. Ermolaeva, A. g Pokatilo, K. I. Polyakova, V. A. Dubovtseva, K. А. Kokushkin, A. V. Devyatkin
"... The report reviews the options of drug supply for patients with chronic hepatitis C in the Russian ..."
 
Vol 8, No 1 (2015) PHARMACOEPIDEMIOLOGICAL EVALUATION OF HEPATOTROPIC THERAPY IN REAL CLINICAL PRACTICE Abstract  similar documents
D. V. Blinov, U. V. Zimovina, T. I. Ushakova
"... Chronic liver diseases are a serious problem and a common cause of suffering and death in all ..."
 
Vol 7, No 1 (2014) CLINICAL AND ECONOMIC ANALYSIS IN ASSESSMENT OF HEALTH CARE TECHNOLOGIES IN HEALTH CARE INSTITUTIONS Abstract  similar documents
I. B. Gaykovaya, A. T. Burbello, A. I. Ermakov, A. S. Fedorenko, T. V. Vavilova, M. V. Komok
"... of chronic infectious and inflammatory diseases and to evaluate the effectiveness of antiplatelet therapy. ..."
 
Vol 8, No 2 (2015) REASONS FOR DIFFICULTY OF THE PHARMACOECONOMIC ANALYSIS FOR ORPHAN DRUGS. WAYS FOR SOLUTIONS Abstract  similar documents
Andrey Vladislavovich Pavlysh, Aleksei Sergeevich Kolbin, Roman Andreevich Gapeshin, Stanislav Mikhailovich Malyshev
"... Orphan drugs are used for treatment of rare life-threatening diseases. There is no universal ..."
 
Vol 6, No 3 (2013) COST-UTILITY ANALYSIS OVER USE OF TYROSINE KINASE INHIBITORS (TASIGNA AND GLEEVEC) FOR TREATMENT OF CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE AS FIRST-LINE THERAPY FOR DE NOVO PATIENTS Abstract  similar documents
R. I. Yagudina, A. Yu. Kulikov, I. A. Komarov
"... Chronic myeloid leukemia (CML) accounts for roughly 20% of leucosis in adults, and this pathology ..."
 
Vol 11, No 2 (2018) Pharmacoeconomic analysis of treatment with nilotinib as the second line therapy in patients with chronic myeloid leukemia Abstract  similar documents
N. A. Avxentyev, M. Yu. Frolov, A. S. Makarov
"... Ilmatinib is currently the most widely used tyrosine kinase inhibitor for the treatment of chronic ..."
 
Vol 7, No 2 (2014) ECONOMIC ANALYSIS OF USE OF IMMUNOCORRECTIVE PREPARATIONS FOR PREVENTION OF OFTEN RESPIRATORY INFECTIONS AND THEIR COMPLICATIONS AT CHILDREN OF SCHOOL AGE Abstract  similar documents
R. V. Maiorov, D. P. Derbenev
"... infections and considerable decrease direct and indirect cost on treatment of respiratory infectious diseases ..."
 
Vol 5, No 1 (2012) EСOLOGO-ECONOMIC PROBLEMS OF TECHNOGENIC INFLUENCE OF POLLUTION ON DISEASE OF THE POPULATION Abstract  similar documents
A. I. Borodin, E. M. Ovchinnikov
"... нетрудоспособность, хроническая заболеваемость, инвалид- ность, т.е. идут процессы потери трудовых ресурсов и ..."
 
Vol 11, No 4 (2018) Modeling the effect of enzyme replacement therapy on life-threatening complications in patients with Fabry disease Abstract  similar documents
V. I. Ignatyeva, S. V. Moiseev, N. M. Bulanov, E. A. Karovajkina, A S. Moiseev
"... Fabry disease (FD) is a severe lysosome storage disease caused by congenital deficiency ..."
 
Vol 8, No 4 (2015) CLINICAL AND ECONOMIC EVALUATION OF THROMBOPOIETIN RECEPTOR AGONISTS IN THE TREATMENT OF CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA IN ADULTS Abstract  similar documents
E. A. Pyadushkina, M. Yu. Frolov, M. V. Avksentyeva
"... ) Eltrombopag and Romiplostim has been performed in patients with chronic idiopathic thrombocytopenic purpura ..."
 
Vol 7, No 4 (2014) APPLICATION OF MULTIPLE-CRITERIA ANALYSIS FOR OPTIMIZATION OF FINANCING OF RARE DISEASES Abstract  similar documents
V. V. Omelyanovskiy, V. K. Fedyaeva, O. Yu. Rebrova
"... financing of rare disease drugs remains a serious problem for both foreign countries and our ..."
 
Vol 7, No 3 (2014) THE ANALYSIS OF METHODOLOGIC CHARACTERISTICS OF RESEARCHES ON SOCIAL AND ECONOMIC BURDEN OF DISEASES IN RUSSIA IN THE FRAMES OF DEVELOPMENT OF STANDARD COST OF ILLNESS METHODOLOGY FOR THE HEALTH TECHNOLOGY ASSESSMENT Abstract  similar documents
V. I. Ignatyeva, M. V. Avxentyeva
"... of social and economic burden of disease) is one of the most widely used. Our objective was to analyze ..."
 
Vol 7, No 4 (2014) ANALYSIS OF GOVERNMENT PROCUREMENTS OF MEDICINES APPLIED IN RARE DISEASES THERAPY Abstract  similar documents
D. V. Fedyaev, V. K. Fedyaeva, V. V. Omelyanovsky
"... diseases. The analysis was conducted on the basis of 1499 selected trade procedures on rare disease drugs ..."
 
Vol 7, No 3 (2014) ASSESSMENT OF NECESSARY FINANCIAL EXPENSES ON THE DRUG SUPPLY OF THE PATIENTS WITH ORPHAN DISEASES IN THE RUSSIAN FEDERATION Abstract  similar documents
M. V. Sura, K. V. Gerasimova, V. V. Omelyanovskiy, M. V. Avksentyeva
"... with orphan diseases, included in the list of orphan diseases (24 diseases) by the RF Government Regulation ..."
 
Vol 11, No 3 (2018) Ocrelizumab – a monoclonal antibody – in the treatment of adult patients with multiple sclerosis: a systematic review Abstract  similar documents
D. L. Klabukova, M. E. Holownia-Voloskova, M. V. Davydovskaya, T. N. Ermolaeva, K. I. Polyakova, A. G. Fisun, K. A. Kokushkin
"... ; the intervention – ocrelizumab; the comparators – all disease-modifying treatments for MS; the outcomes ..."
 
Vol 7, No 1 (2014) PATIENTS WITH NEUROLOGICAL DISEASES: RATIONALE FOR PHARMACOECONOMIC EVALUATION OF COST OPTIMIZATION FOR MANAGEMENT WITH NEURON-SPECIFIC PROTEINS ASSESSMENT AS MARKERS OF INCREASED BLOOD-BRAIN-BARRIER PERMEABILITY Abstract  similar documents
D. V. Blinov
"... for NSP after the perinatal hypoxic-ischemic lesion of the CNS which reflects the chronic course ..."
 
Vol 9, No 2 (2016) EPIDEMIOLOGICAL FEATURES OF NON-ALCOHOLIC FATTY LIVER DISEASE IN NOVOSIBIRSK (SIBERIAN FEDERAL DISTRICT): REGIONAL DATA OF OPEN MULTICENTER PROSPECTIVE STUDY DIREG 2 Abstract  similar documents
V. V. Tsukanov, A. S. Yurkina, T. A. Ushakova, D. V. Blinov
"... Non-alcoholic fatty liver disease (NAFLD) is an important medical and social problem. Essentially ..."
 
Vol 6, No 4 (2013) Pharmacoeconomical analysis of use of the low-molecular weight heparins for prevention of the venous tromboembolism in the conditions of multidisciplinary hospital Abstract  similar documents
A. S. Kolbin, I. A. Vilyum, M. A. Proskurin, Yu. E. Balykina
"... тяжелой почечной недостаточностью с высоким риском развития венозных тромбоэмболических осложнений при ..."
 
1 - 25 of 112 Items 1 2 3 4 5 > >> 

Search tips:

  • Search terms are case-insensitive
  • Common words are ignored
  • By default articles containing any term in the query are returned (i.e., OR is implied)
  • Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
  • Combine multiple words with AND to find articles containing all terms; e.g., education AND research
  • Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
  • Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
  • Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)